GlassScriptPhysician profile
Yancheng Luo
NPI 1639520547
$4,548.44
in general payments reported to CMS, 2019-2025
8 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 79% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $133 · 2023: $1,556 · 2024: $505 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126 · Travel and Lodging: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.93 |
| Travel and Lodging | $2,106.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $3,194.11 | 2023-2025 | Vns Therapy |
| Jazz Pharmaceuticals INC. | $597.52 | 2022-2025 | |
| Neurelis, INC. | $198.46 | 2021-2023 | Valtoco |
| Ucb, INC. | $145.60 | 2021-2024 | Nayzilam |
| Sk Life Science, INC. | $128.37 | 2023 | Xcopri |
| Immedica Pharma US, INC. | $117.49 | 2024 | |
| Genentech USA, INC. | $105.95 | 2024 | Evrysdi |
| Zogenix INC. | $60.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yancheng Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.